Literature DB >> 25850602

An Unusual Case of Constitutional Mismatch Repair Deficiency Syndrome With Anaplastic Ganglioglioma, Colonic Adenocarcinoma, Osteosarcoma, Acute Myeloid Leukemia, and Signs of Neurofibromatosis Type 1: Case Report.

Badih Daou1, Marc Zanello, Pascale Varlet, Laurence Brugieres, Pascal Jabbour, Olivier Caron, Noémie Lavoine, Frederic Dhermain, Christophe Willekens, Frederic Beuvon, David Malka, Emmanuèle Lechapt-Zalcmann, Georges Abi Lahoud.   

Abstract

BACKGROUND AND IMPORTANCE: Constitutional mismatch repair deficiency (CMMRD) syndrome is a disorder with recessive inheritance caused by biallelic mismatch repair gene mutations, in which mismatch repair defects are inherited from both parents. This syndrome is associated with multiple cancers occurring in childhood. The most common tumors observed with CMMRD include brain tumors, digestive tract tumors, and hematological malignancies. The aim of this study was to report new phenotypic expressions of CMMRD syndrome and add new insight to the existing knowledge about this disease. A review of the literature was conducted and recommendation for surveillance and follow-up in patients with CMMRD are proposed. CLINICAL
PRESENTATION: We report for the first time in the literature, the case of a 22-year-old female patient who was diagnosed with CMMRD syndrome, with the development of 2 unusual tumors: an anaplastic ganglioglioma and an osteosarcoma. She presented initially with an anaplastic ganglioglioma and later developed several malignancies including colonic adenocarcinoma, osteosarcoma, and acute myeloid leukemia. The patient had an atypical course of her disease with development of the initial malignancy at an older age and a remarkably long survival period despite developing aggressive tumors.
CONCLUSION: Many aspects of this disease are still unknown. We identified a case of CMMRD in a patient presenting with an anaplastic ganglioglioma, who underwent successful surgical resection, chemotherapy, and radiotherapy and has had one of the longest survival periods known with this disease. This case broadens the tumor spectrum observed with CMMRD syndrome with anaplastic ganglioglioma and osteosarcoma as new phenotypic expressions of this genetic defect.

Entities:  

Mesh:

Year:  2015        PMID: 25850602     DOI: 10.1227/NEU.0000000000000754

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  5 in total

1.  Impact of surgery, adjuvant treatment, and other prognostic factors in the management of anaplastic ganglioglioma.

Authors:  Supriya Mallick; Rony Benson; Wineeta Melgandi; Prashanth Giridhar; G K Rath
Journal:  Childs Nerv Syst       Date:  2018-03-29       Impact factor: 1.475

Review 2.  The Challenge of Diagnosing Constitutional Mismatch Repair Deficiency Syndrome in Brain Malignancies from Young Individuals.

Authors:  Cristina Carrato; Carolina Sanz; Ana María Muñoz-Mármol; Ignacio Blanco; Marta Pineda; Jesús Del Valle; Estela Dámaso; Manel Esteller; Eva Musulen
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

3.  Constitutional mismatch repair deficiency-associated brain tumors: report from the European C4CMMRD consortium.

Authors:  Léa Guerrini-Rousseau; Pascale Varlet; Chrystelle Colas; Felipe Andreiuolo; Franck Bourdeaut; Karin Dahan; Christine Devalck; Cécile Faure-Conter; Maurizio Genuardi; Yael Goldberg; Michaela Kuhlen; Salma Moalla; Enrico Opocher; Vanessa Perez-Alonso; Astrid Sehested; Irene Slavc; Sheila Unger; Katharina Wimmer; Jacques Grill; Laurence Brugières
Journal:  Neurooncol Adv       Date:  2019-12-02

Review 4.  Constitutional mismatch repair-deficiency: current problems and emerging therapeutic strategies.

Authors:  Malak Abedalthagafi
Journal:  Oncotarget       Date:  2018-10-23

5.  Mismatch repair deficiency is rare in bone and soft tissue tumors.

Authors:  Suk Wai Lam; Marie Kostine; Noel F C C de Miranda; Patrick Schöffski; Che-Jui Lee; Hans Morreau; Judith V M G Bovée
Journal:  Histopathology       Date:  2021-06-08       Impact factor: 5.087

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.